NASDAQ: CGCCanopy Growth Corp Stock
$8.97-0.06 (-0.66%)
Updated Apr 24, 2024
CGC Price
$8.97
Fair Value Price
N/A
Market Cap
$817.30M
52 Week Low
$2.76
52 Week High
$19.20
P/E
-0.55x
P/B
2.01x
P/S
1.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$246.67M
Earnings
-$959.81M
Gross Margin
-14.1%
Operating Margin
-386.99%
Profit Margin
-386.2%
Debt to Equity
1.5
Operating Cash Flow
-$300M
Beta
1.48
Next Earnings
Jun 20, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CGC Overview
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CGC is good value based on its book value relative to its share price (2.01x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.06x)
P/B vs Industry Valuation
CGC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CGC due diligence checks available for Premium users.
Be the first to know about important CGC news, forecast changes, insider trades & much more!
CGC News
Valuation
CGC fair value
Fair Value of CGC stock based on Discounted Cash Flow (DCF)
Price
$8.97
Fair Value
$140.49
Undervalued by
93.62%
CGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.55x
Industry
47.66x
Market
41.27x
CGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
2.06x
CGC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGC's financial health
Profit margin
Revenue
$59.0M
Net Income
-$163.0M
Profit Margin
-276.2%
CGC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CGC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.0B
Liabilities
$612.8M
Debt to equity
1.5
CGC's short-term assets ($296.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGC's long-term liabilities ($443.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.5M
Investing
-$459.4k
Financing
-$49.8M
CGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGC vs Pharmaceutical Stocks
Canopy Growth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.